Clinical Trials

Animate Biosciences Delivers Ai Designed Peptides That Match Standard Of Care In Pulmonary Fibrosis Model

Animate Biosciences announces positive preclinical results from a mouse model of pulmonary fibrosis demonstrating that two of its AI-designed therapeu...

 January 15, 2026 | News

Management of Relapsed/Refractory Multiple Myeloma

Doctors and researchers have made huge steps in treating this blood cancer lately. Yet, most people face a time when the cancer returns or stops responding...

 January 14, 2026 | News

Suvoda Builds A Unified Clinical Trial Platform Through Greenphire Merger And AI Innovation In 2025

Suvoda, a clinical trial technology company, took decisive steps in 2025 toward a more connected and streamlined clinical trial experience for both patient...

 January 14, 2026 | News

WuXi Biologics Secures UK MHRA GMP Clearance For Wuxi Ophthalmic Manufacturing Sites

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing ...

 January 14, 2026 | News

Formosa Pharmaceuticals Secures Strategic Korea Commercial Partner For Its FDA Approved Ophthalmic Therapy

 Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced  that the company has entered into an exclusive licensing agreement with Sam...

 January 13, 2026 | News

Lynk Pharmaceuticals Delivers Breakthrough Phase Three Win For Oral Rheumatoid Arthritis Therapy

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development company focused on develop...

 January 13, 2026 | News

FDA Signals A Faster Regulatory Path For Cell And Gene Therapies

  The U.S. Food and Drug Administration  announced it is sharing information about the agency’s flexible appro...

 January 13, 2026 | News

M&G Leads $50 Million Series C In bit.bio To Scale Human Cell Programming

M&G Investments (M&G) announces that it has led a US$50 million Series C funding round for bit.bio, the Cambridge-based biotech company pionee...

 January 12, 2026 | News

Johnson And Johnson Amivantamab Combo Delivers 73% Response Rate In First Line Metastatic Colorectal Cancer

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable res...

 January 12, 2026 | News

AirNexis Secures Global Rights To Phase 2 COPD Asset AN01 In $200 Million Series A Backed By Frazier And OrbiMed

AirNexis acquires exclusive rights to develop AN01 outside of China from Haisco Pharmaceutical Group Company founded by Frazier Life Sciences, which led...

 January 12, 2026 | News

Biocytogen And Acepodia Advance Dual Payload Bispecific ADC Strategy Through Option Based Licensing Pact

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), announced that the companies have entered int...

 January 12, 2026 | News

Oxeia Targets First Ever Treatment For Persistent Concussion Symptoms After Strong Phase 2a Results

Biotech showed 85% patient improvement in Phase 2a trial—zero approved treatments exist for persistent concussion symptoms Oxeia Biopharmaceuticals ...

 January 09, 2026 | News

Thermo Fisher Scientific Enrols First Patient In New CorEvitas Obesity Registry

Thermo Fisher Scientific Inc., the world leader in serving science,announced the enrollment of the first patient in the new PPD™ CorEvitas™ Obe...

 January 08, 2026 | News

ProBioGen Signs Master Service Agreement With Zag Bio To Advance Thymus Targeted Antibody Programme

 ProBioGen announced the signing of a Master Service Agreement ("MSA") with Zag Bio, Inc., a biotechnology company developing thymus-targete...

 January 07, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close